Statement by Chip Davis, President and CEO, GPHA, Regarding Medicare Costs
July 26th 2016A new report from the Office of the Actuary shows that the cost of Medicare's catastrophic prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015, largely because of rising brand drug costs."
Read More
FDA Approves Expanded Indication for Synjardy
July 25th 2016The FDA has approved an expanded indication for type 2 diabetes treatment Synjardy (empagliflozin and metformin hydrochloride) to include treatment-naïve adults. Synjardy is designed to improve glycemic control in adults with type 2 diabetes.
Read More